2024/11/01 22:02:07 | |
---|---|
Price | |
98.55 EUR | |
Difference | 1.07% (1.04) |
ISIN | FR0000120578 |
Symbol | SAN |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 123,729 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | 98.48 EUR (110) |
Ask (Ask size) | 98.62 EUR (110) |
Open | 97.46 EUR |
High | 99.00 EUR |
Low | 97.42 EUR |
Close (prev. day) | 97.51 EUR |
VWAP | 98.37794 EUR |
Volume (pcs) | 2,012 |
Trading volume | 197,936.42 |
Number of trades | 44 |
Last size | 50 |
Related Futures | 53 |
Related Options | - |
Date | Headline | Download | |
2024/10/29 | Global Equity Ratings | ||
2024/10/29 | Aktienempfehlungen Global | ||
2024/10/22 | Global Equity Ratings | ||
2024/10/22 | Aktienempfehlungen Global | ||
2024/09/27 | Global Equity Ratings |
2024/11/01 22:02:07 | |
---|---|
Price | |
98.55 EUR | |
Difference | 1.07% (1.04) |
ISIN | FR0000120578 |
Symbol | SAN |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 123,729 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | 98.48 EUR (110) |
Ask (Ask size) | 98.62 EUR (110) |
Open | 97.46 EUR |
High | 99.00 EUR |
Low | 97.42 EUR |
Close (prev. day) | 97.51 EUR |
VWAP | 98.37794 EUR |
Volume (pcs) | 2,012 |
Trading volume | 197,936.42 |
Number of trades | 44 |
Last size | 50 |
6M | 1Y | 3Y | |
Perf (%) | +5.76% | +13.42% | +12.31% |
Perf (abs.) | +5.31 | +11.54 | +10.69 |
Beta | 0.48 | 0.61 | 0.43 |
Volatility | 20.16 | 18.85 | 25.09 |
Ø price 5 days | Ø volume 5 days (pcs.) | 99.41 EUR (5,279) |
Ø price 30 days | Ø volume 30 days (pcs.) | 100.69 EUR (4,402) |
Ø price 100 days | Ø volume 100 days (pcs.) | 97.55 EUR (5,182) |
Ø price 250 days | Ø volume 250 days (pcs.) | 92.51 EUR (6,129) |
YTD High | date | 106.12 EUR (2024/09/05) |
YTD Low | date | 84.94 EUR (2024/02/14) |
52 Weeks High | date | 106.12 EUR (2024/09/05) |
52 Weeks Low | date | 82.93 EUR (2023/11/07) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/11/01 | 17:35 | 98.72 EUR | 0.22 | 41 |
Vienna Stock Exchange | 2024/11/01 | 15:30 | 98.52 EUR | 0.00 | 4 |
Tradegate | 2024/11/01 | 22:02 | 98.55 EUR | 0.20 | 44 |
Stuttgart | 2024/11/01 | 21:55 | 98.53 EUR | 0.00 | 64 |
Munich | 2024/11/01 | 08:04 | 97.80 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/11/01 | 17:30 | 98.765 EUR | 0.04 | 4 |
Hanover | 2024/11/01 | 17:25 | 98.63 EUR | 0.00 | 2 |
Hamburg | 2024/11/01 | 17:25 | 98.64 EUR | 0.00 | 2 |
Frankfurt | 2024/11/01 | 15:52 | 98.63 EUR | 0.02 | 4 |
FINRA other OTC Issues | 2024/11/01 | 19:52 | 108.736 USD | 0.03 | 5 |
Euronext Paris | 2024/11/01 | 17:35 | 98.70 EUR | 107.93 | 9,343 |
Euronext Milan MTF Trading After Hours | 2024/10/29 | 19:19 | 103.04 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/11/01 | 17:44 | 98.69 EUR | 0.01 | 4 |
Duesseldorf | 2024/11/01 | 19:30 | 97.98 EUR | 0.00 | 5 |
Berlin | 2024/11/01 | 08:08 | 97.48 EUR | 0.00 | 1 |
SANOFI |
- - |
46, avenue de la Grande Armée - 75017 Paris |
Telefon: +33-1-53-77-40-00 |
Fax: +33-1-53-77-44-03 |
E-mail: - |
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France. |
Paul Hudson | Chairman of Managing Board |
Brendan O'Callaghan | Member of Executive Committee |
Brian Foard | Member of Executive Committee |
Emmanuel Frenehard | Member of Executive Committee |
Francois Roger | Member of Executive Committee |
Houman Ashrafian | Member of Executive Committee |
Julie Van Ongevalle | Member of Executive Committee |
Madeleine Roach | Member of Executive Committee |
Natalie Bickford | Member of Executive Committee |
Olivier Charmeil | Member of Executive Committee |
Roy Papatheodorou | Member of Executive Committee |
Thomas Triomphe | Member of Executive Committee |
Frédéric Oudéa | Chairman of Supervisory Board |
Antoine Yver | Member of Supervisory Board |
Emile Voest | Member of Supervisory Board |
John Sundy | Member of Supervisory Board |
Wolfgang Laux | Member of Supervisory Board |
Anne-Francoise Nesmes | Member of Supervisory Board |
Barbara Lavernos | Member of Supervisory Board |
Carole Ferrand | Member of Supervisory Board |
Christophe Babule | Member of Supervisory Board |
Clotilde Delbos | Member of Supervisory Board |
Fabienne Lecorvaisier | Member of Supervisory Board |
Gilles Schnepp | Member of Supervisory Board |
Lise Kingo | Member of Supervisory Board |
Patrick Kron | Member of Supervisory Board |
Rachel Duan | Member of Supervisory Board |
Yann Tran | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.